System and method for determining infraspectral markers using transdermal infrared optics
One or more aspects of the technical solutions described herein facilitate using transdermal infrared optics to discover infraspectral markers. The infraspectral markers can predict presence/absence of one or more physiological state in a subject. One or more aspects of the technical solutions described herein further facilitate continuous monitoring and prediction of trends of a physiological state of a subject using non-invasive transdermal infrared optics. Further, one or more aspects of the technical solutions described herein facilitate personalized triage of and alerts for a subject based on continuous monitoring of non-invasive transdermal optical infraspectral markers.
1 . An analysis system comprising:
a memory; and
one or more processors coupled with the memory, the one or more processors being configured to:
access a plurality of optical scans of a subject, the subject having a physiological state, the optical scans being captured by an optical monitoring device in a transdermal manner;
identify an infraprofile by analyzing the optical scans, wherein the infraprofile comprises an optical infrared signature representative of the physiological state of the subject, the infraprofile including one or more inframarkers derived from optical measurements from the optical scans, wherein the infraprofile identifies the physiological state directly based on the optical infrared signature independently of determining a corresponding biomarker or a composite of corresponding biomarkers; and
output the infraprofile as a non-invasive identifier of the physiological state of the subject;
access a first optical scan of the subject, the first optical scan comprising a first measurement of an inframarker;
calculate a difference between the first measurement of the inframarker and a baseline measurement of the inframarker, the baseline measurement of the inframarker being customized for the subject based on data from a predetermined number of optical scans; and
in response to the difference exceeding a delta, add the inframarker to the infraprofile of the physiological state; and
wherein the one or more inframarkers includes a specific inframarker configured as the optical infrared signature representative of a specific biomarker, and the optical infrared signature includes a combination of absorption peaks unique to the specific biomarker.
2 . The analysis system of claim 1 , wherein the one or more processors are further configured to:
store the infraprofile to a database;
receive subject information related to the subject; and
associate the subject information with the infraprofile in the database.
3 . The analysis system of claim 2 , wherein the subject information includes at least one of identifying information, demographics, comorbidities, clinical findings, diagnosis, medications, or vital data of the subject.
4 . The analysis system of claim 1 , further comprising:
an inframarker configuration for configuring the optical monitoring device to detect a selected inframarker of the one or more inframarkers.
5 . The analysis system of claim 1 , the one or more inframarkers including a first inframarker and an at least second inframarker; the analysis system further comprising:
a first inframarker configuration for configuring the optical monitoring device to detect the first inframarker of the subject;
an at least second inframarker configuration for configuring the optical monitoring device to detect the at least second inframarker of the subject.
6 . The analysis system of claim 5 , wherein:
the first inframarker predicts a first physiological state of the subject; and
the at least second inframarker predicts an at least second physiological state of the subject which is different from the first physiological state.
7 . The analysis system of claim 6 , wherein the first inframarker is representative of a progression stage of a disease; and
the at least second inframarker is representative of another progression stage of the disease.
8 . The analysis system of claim 7 , wherein the disease is cancer.
9 . The analysis system of claim 7 , wherein the disease is heart disease.
10 . The analysis system of claim 5 , wherein:
the first inframarker is associated with a first subject condition; and
the at least second inframarker is associated with an at least second subject condition which is different from the first subject condition.
11 . The analysis system of claim 10 , wherein the first subject condition is a treatment of a disease, the treatment administered to the subject; and
the at least second subject condition is another treatment of the disease, the another treatment administered to the subject.
12 . The analysis system of claim 11 , wherein the treatment includes administering a drug to the subject; and
the another treatment includes administering another drug to the subject, the another drug being different from the drug.
13 . The analysis system of claim 1 , wherein the infraprofile represents the physiological state of the subject without corresponding to a known biomarker.
14 . The analysis system of claim 1 , wherein the one or more processors are further configured to identify the infraprofile using an inframarker configuration that represents a disease journey comprising a series of disease phenotypes associated with the physiological state of the subject.
15 . The analysis system of claim 14 , wherein the one or more processors are further configured to support precision medicine by performing disease phenotyping and risk stratification for the subject based on the identified infraprofile and the inframarker configuration.
16 . The analysis system of claim 14 , wherein the one or more processors are further configured to facilitate drug discovery by analyzing infraprofiles derived from infraspectral markers across a plurality of subjects using the inframarker configuration.
17 . The analysis system of claim 1 , wherein the optical monitoring device captures the plurality of optical scans in the transdermal manner using infrared spectroscopy in a mid-infrared range of the electromagnetic spectrum to generate the optical measurements forming the inframarkers.
18 . The analysis system of claim 17 , wherein the mid-infrared range includes wavelengths from 5 micrometers to 12.5 micrometers.